In a sweeping pretrial conference order, Judge Rodney Gilstrap ruled on 23 contested motions in Stratasys’s 3D-printing patent case against Bambu Lab — letting most patents advance to trial while striking key portions of Stratasys’s damages theory.
The Federal Circuit vacated a district court ruling that two “executable program code” limitations in TrackTime’s audio-synchronization patents were means-plus-function terms, remanding for fresh analysis under the intervening Dyfan precedent, while affirming invalidity of a related patent claim for anticipation.
The Federal Circuit affirmed that “mounted on” in a video laryngoscope patent means fastened to the exterior of the blade — not merely positioned inside with an exposed lens — ending a 16-year patent infringement battle.
A Colorado federal judge grants Amgen a preliminary injunction blocking the state’s first-in-the-nation Enbrel price cap, finding that capping the price of a patented drug is not a permissible option for states under federal patent law.
A split Federal Circuit affirms the patent claim construction that kept a generic Nuedexta competitor off the market, but vacates the bond waiver and orders the district court to set a proper security amount.
A Western District of Washington court denied Zillow’s motion to dismiss IBM’s single sign-on authentication patent claim (U.S. Patent No. 7,631,346), sending the case toward trial and potentially exposing platforms using federated login to similar claims.
A Delaware federal court held that HP, Dell, and ASUS acquired implied licenses to LiTL’s portable computer patents through a component supplier’s express license, granting summary judgment for the laptop makers under the legal estoppel doctrine.
A Delaware court ruled that HP, Dell, and ASUS hold implied patent licenses through their unnamed component supplier’s settlement with LiTL LLC, granting summary judgment of noninfringement on all six asserted portable-computer design patents.
The Patent Trial and Appeal Board issued a split final written decision in a pair of inter partes review proceedings filed by ResMed Corp., finding one Cleveland Medical Devices sleep apnea treatment patent unpatentable while upholding claims in a closely related companion patent, illustrating the all-or-nothing stakes of IPR litigation on patent families.
The U.S. International Trade Commission instituted Investigation No. 337-TA-1508 on a complaint by Seer, Inc. and Brigham and Women’s Hospital against Chinese proteomics company Nanomics Biotechnology, alleging infringement of patents covering AI-enabled protein analysis systems and seeking an exclusion order on Nanomics’ imports.
The D.C. Circuit held that a generic drugmaker cannot escape a Hatch-Waxman patent judgment by amending its drug application — the bar on FDA approval runs to the application number itself, not to any particular labeled indication.
An Eastern District of Texas jury awarded Vasu Holdings $3 million after finding Samsung’s Galaxy smartphones infringed a wireless roaming patent, while clearing Samsung on two other asserted patents.
A Delaware federal judge found that supplement maker Elysium Health failed to prove inequitable conduct or unclean hands by W.R. Grace in connection with nicotinamide riboside patents — leaving intact a $3.6 million willful infringement verdict.
A PTAB leadership panel on June 26, 2026 reversed the Board’s earlier cancellation of an Express Mobile website-building patent, holding that PTAB should not reach a different validity outcome than the jury when both forums consider the same evidence — a ruling with broad implications for GoDaddy’s $253M exposure.
The U.S. International Trade Commission issued a final determination that Voltage LLC violated Section 337 by importing solar trunk bus cable assemblies that infringe two Shoals Technologies patents, imposing a limited exclusion order and 100% bond during presidential review.
Mr. Justice Meade ordered Warner Bros. Discovery and Paramount to make interim RAND payments to Nokia for video streaming codec standard-essential patents, finding that the Nokia Lump Sum Offer was the most credible interim payment benchmark, while discounting Nokia’s claim to full royalties going back to 2011 due to its late-arriving licensing programme.
The PTAB held that a child patent in a continuation family is not invalid for obviousness-type double patenting (ODP) if its expiration date does not exceed the original patent’s expiration date — including any patent term adjustment (PTA) — providing important clarity for continuation patent strategy.
USPTO Director John Squires vacated a PTAB panel’s obviousness finding on U.S. Patent No. 11,828,425, ruling the Board failed to explain why its conclusion on claim 2 differed from a jury verdict finding the same claim valid and infringed — reinforcing the September 2025 PTAB parallel-proceedings memorandum.
The Federal Circuit affirmed invalidation of Enanta’s Paxlovid-related patent because its 2020 provisional application disclosed ‘C2’ alkyl groups while the issued patent claimed ‘C1,’ a difference of one carbon atom that broke the priority chain and exposed the claims to anticipation by Pfizer’s prior disclosure of nirmatrelvir.
The Federal Circuit affirmed Intel’s summary judgment win, finding PACT XPP forfeited its capability-based infringement theory on the ‘301 patent and that prosecution statements during ex parte reexamination narrowed the ‘593 patent’s ‘physically dedicated connection’ claim to exclude Intel’s shared-bus architecture.
The Fourth Circuit affirmed that Sophos’s post-acquisition antivirus products were not “derivations” of the named containerization products in a 2016 patent license agreement, even though they shared some common source code, because the shared code was inactive in the original products and the newer products did not originate from them.
USPTO Director Squires issued a precedential decision vacating three IPR institution grants after a federal court found all challenged Lightning Roulette patents invalid under § 101, while simultaneously establishing a new 30-day deadline for parties to request Director Review of institution decisions.
The UPC Düsseldorf Local Division rules that Article 72 UPCA’s five-year limitation period covers only financial compensation — not injunctions — confirming that patent holders face no time bar on seeking pan-European injunctive relief regardless of when infringement was discovered.
A federal jury in the Eastern District of Texas awarded Aspen Networks $190 million, finding that Verizon Wireless infringed U.S. Patent No. 8,009,554 covering the core technology enabling seamless Wi-Fi/cellular call handoff (VoWi-Fi).
Judge Noreika invalidates Novartis subsidiary’s patents covering Lutathera (lutetium-177 dotatate) cancer drug, finding all asserted claims invalid under the on-sale bar — clearing a potential path for generic competition.
The Federal Circuit reversed and remanded a district court’s IPR estoppel ruling for the second time, holding that a classification search returning 26,333 results cannot show a prior art reference was “reasonably discoverable,” and that Cardinal IP’s search evidence for a second invalidity ground was tainted by hindsight bias throughout.
In a precedential decision, the Federal Circuit reversed district court estoppel orders that had blocked Valve from using two prior-art grounds at trial, holding that classification searches returning 26,333 results do not establish discovery and that hindsight-infected forward citation searches cannot prove what a 2016 petitioner reasonably could have raised.
The Federal Circuit affirmed denial of a preliminary injunction sought by Boston Scientific to block Stryker’s OptaBlate BVN spine pain device, finding substantial questions about whether Stryker’s product meets the patent’s introducer placement requirements.
Judge Albright denies Acer’s post-trial JMOL motion, upholding a $10.3 million jury verdict for SVV Technology Innovations on LED display technology patents covering gaming monitors.
The U.S. International Trade Commission announced it will review portions of the administrative law judge’s determination that GoTrax and Gyroor infringed Razor USA’s hoverboard patents, with a limited exclusion order and cease-and-desist orders recommended by the ALJ pending Commission review.
A federal judge in Delaware denied Guardant Health’s post-trial motions seeking to overturn or modify the jury’s $83.4 million verdict for willful infringement of University of Washington duplex consensus sequencing patents exclusively licensed to TwinStrand Biosciences.
Judge Gregory Williams of the District of Delaware denied GlaxoSmithKline’s motions to dismiss prosecution laches defenses asserted by Pfizer/BioNTech and Moderna, finding the defendants plausibly alleged that GSK unreasonably delayed patent prosecution for over a decade and then broadened mRNA vaccine claims only after its rivals’ COVID vaccine technology became public.
The Federal Circuit affirmed a PTAB inter partes review finding that claims of Medmix’s fluid-mixing patent (U.S. 9,010,578) are obvious, rejecting the patent owner’s narrow claim construction for ‘at least two ramps’ and upholding the Board’s motivation-to-combine analysis.
Judge Jacqueline Scott Corley of the Northern District of California dismissed TDK Corporation of Japan from a piezoelectric MEMS patent infringement suit, holding that conclusory stream-of-commerce allegations were insufficient to establish personal jurisdiction and that plaintiff lacked a legitimate basis for naming the Japanese parent company as a defendant.
Judge Araceli Martínez-Olguín of the Northern District of California awarded Favored Tech $2,208,115.77 in attorney’s fees under 35 U.S.C. § 285 after finding that P2I Ltd.’s nano-coating patent infringement case was exceptional due to bad faith litigation conduct.
A Delaware federal jury found that TVision Insights did not infringe Nielsen’s patent covering digital-signature technology used to identify audio content for television audience measurement, handing TVision a trial victory in a long-running patent dispute over audience-tracking methods.
A Delaware jury unanimously found that Amgen’s Teneobio subsidiary willfully infringed Harbour Antibodies’ foundational patent on transgenic mouse platforms for generating fully human monoclonal antibodies, awarding $20.2 million in damages that could be trebled to $60.6 million for willfulness.
A Delaware federal jury finds Amgen and its subsidiary Teneobio willfully infringed a foundational patent covering the production of heavy chain-only antibodies in transgenic mice, awarding $20.2 million in damages — the full amount requested by the plaintiffs.
A new PTAB panel — assembled after a conflict-of-interest controversy forced removal of the original APJ — issues a second Final Written Decision finding U.S. Patent No. 9,917,856 unpatentable on obviousness grounds, dealing another blow to Centripetal Networks’ once-$1.9 billion patent assertion against Cisco.
A Virginia federal judge denied Altria Group and NJOY’s motion for a preliminary injunction to halt an ITC patent investigation over vaping device patents, rejecting the companies’ argument that the ITC’s administrative law judge appointment process is unconstitutional.
The Patent Trial and Appeal Board upheld two Zaxcom wireless audio recording patents in back-to-back IPR final written decisions, finding that Academy Award and Emmy Award recognition for the technology defeated RØDE Microphones’ obviousness challenge.
The Federal Circuit affirmed the dismissal of DynaPass’s infringement claim against Bank of America, holding that the claim term ‘receiving the password’ requires the user to submit a pre-combined passcode-and-token password — not submit the two components separately as BofA’s mobile banking app does.
Judge Jennifer L. Hall of the District of Delaware denied Ferring’s post-trial motions, preserving a $25 million jury verdict in favor of Finch Therapeutics and the University of Minnesota on three fecal microbiota transplant patents covering Ferring’s Rebyota product.
The Patent Trial and Appeal Board invalidated all claims of Inari Medical’s U.S. Patent No. 11,554,005 covering a system for treating embolism, finding the claims anticipated by and obvious over prior art in a Final Written Decision from IPR2025-00289.
The Patent Trial and Appeal Board issued split decisions in Stratasys Inc.’s ongoing patent dispute with Chinese 3D-printing rival Bambu Lab and its parent Shenzhen Tuozhu Technology, invalidating claims in one Stratasys patent while upholding another covering networked 3D printing.
The PTAB issues a Final Written Decision upholding Yangtze Memory Technologies’ U.S. patent on electrostatic discharge bus architecture, rejecting Micron’s invalidity challenge — and earlier rejecting Micron’s novel argument that national security grounds should shield the IPR from Board review.
The Federal Circuit reversed PTAB’s finding that Sonos’s IPR challenge anticipated Google’s hotword-detection coordination patents, holding the Board’s key factual finding lacked substantial evidence.
The Federal Circuit affirmed the PTAB’s obviousness rejection of a pro se inventor’s patent application for an automated kitchen system, holding that substantial evidence supported the motivation to combine the cited prior art references.
A New Jersey federal court allowed WinView’s direct patent infringement claims against FanDuel to proceed, while dismissing with prejudice the indirect and willful infringement counts for failure to plead pre-suit knowledge — the same result previously reached in a parallel WinView case against DraftKings.
The Federal Circuit affirmed that claim 18 of Purdue Pharma’s patent on abuse-deterrent OxyContin — covering tablets heated in a coating pan — was obvious in light of prior German pharmaceutical art, ending a litigation effort by Purdue’s successor Knoa Pharma.